8-K current report · filed Aug 31, 2026

Biomarin Pharmaceutical Inc (BMRN) 8-K Current Report: August 31, 2026

Item 1.01Item 7.01Item EX-99.1BMRN overview

Short answer

Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on August 31, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). BioMarin grants Ascendis global rights to TransCon CNP, navepegritide, and Yuviwel products.

Biomarin Pharmaceutical Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • BioMarin grants Ascendis global rights to TransCon CNP, navepegritide, and Yuviwel products
  • Royalty stream: 20% of U.S. net sales and 18% in the EU, Brazil, and South Korea through May 2030
  • Settlement ends all pending patent litigation, with Ascendis barred from challenging BioMarin patents
  • License covers achondroplasia, hypochondroplasia, and potential future indications
  • Binding term sheet remains effective if definitive agreement is not signed by September 24, 2026

Item 7.01 · Regulation FD Disclosure

  • BioMarin announced execution of a Term Sheet, signaling a potentially material transaction or strategic arrangement
  • Exhibit 99.1 contains the press release and terms investors need to assess scope, obligations, and financial impact

Item EX-99.1 · Exhibit EX-99.1

  • Global patent settlement with Ascendis eliminates pending ITC and international litigation over Yuviwel
  • Ascendis royalties to BioMarin: 20% of U.S. net sales retroactive to launch
  • 18% royalties on Yuviwel net sales in the EU, Brazil and South Korea through May 2030
  • License covers current and potential indications, including achondroplasia and hypochondroplasia
  • Financial upside depends on Yuviwel sales and BioMarin’s ability to enforce the agreement

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Biomarin Pharmaceutical Inc 8-K filings

Get the next BMRN 8-K as it lands

Follow BMRN for push alerts, or ask the research agent what this filing means.